A large body of evidence indicates that proteinuria is a strong predictor of morbidity, a cause of inflammation, oxidative stress and progression of chronic kidney disease, and development of cardiovascular disease. The processes that lead to proteinuria are complex and involve factors such as glomerular hemodynamic, tubular absorption, and diffusion gradients. Alterations in various different molecular pathways and interactions may lead to the identical clinical end points of proteinuria and chronic kidney disease. Glomerular diseases include a wide range of immune and nonimmune insults that may target and thus damage some components of the glomerular filtration barrier. In many of these conditions, the renal visceral epithelial cell (podocyte) responds to injury along defined pathways, which may explain the resultant clinical and histological changes. The recent discovery of the molecular components of the slit diaphragm, specialized structure of podocyte-podocyte interaction, has been a major breakthrough in understanding the crucial role of the epithelial layer of the glomerular barrier and the pathogenesis of proteinuria. Thispaper provides an overview and update on the structure and function of the glomerular filtration barrier and the pathogenesis of proteinuria, highlighting the role of the podocyte in this setting. In addition, current antiproteinuric therapeutic approaches are briefly commented. 1. Introduction Proteinuria is considered a major healthcare problem that affects several hundred million people worldwide. In addition, proteinuria is a sensitive marker for progressive renal dysfunction and it is considered an independent risk factor for cardiovascular (CV) morbidity and mortality . Furthermore, it is widely accepted that microalbuminuria (albumin urinary excretion of 30？mg–300？mg/day) is the earliest clue about the renal involvement of diabetes, obesity, and the metabolic syndrome. Interestingly, while microalbuminuria is more predictive of reaching CV end points than kidney end points, macroalbuminuria (total protein urinary excretion >500？mg/day) has been demonstrated to be more associated with reaching kidney end points . However, microalbuminuria can often progress to overt proteinuria leading 10–50% of the patients to end-stage kidney disease development, ultimately requiring dialysis or transplantation. Of similar importance is the observation that even levels of albumin under the microalbuminuria threshold (so-called ‘‘high normal’’) are associated with an increased risk for CV outcomes . Therefore, a reduction or
A. K. Bello, B. Hemmelgarn, A. Lloyd et al., “Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 6, pp. 1418–1426, 2011.
P. E. de Jong, R. T. Gansevoort, and S. J. L. Bakker, “Macroalbuminuria and microalbuminuria: do both predict renal and cardiovascular events with similar strength?” Journal of Nephrology, vol. 20, no. 4, pp. 375–380, 2007.
A. S. Levey, D. Cattran, A. Friedman et al., “Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration,” American Journal of Kidney Diseases, vol. 54, no. 2, pp. 205–226, 2009.
B. R. Hemmelgarn, B. J. Manns, A. Lloyd et al., “Relation between kidney function, proteinuria, and adverse outcomes,” The Journal of the American Medical Association, vol. 303, no. 5, pp. 423–429, 2010.
H. L. Hillege, V. Fidler, G. F. H. Diercks et al., “Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population,” Circulation, vol. 106, no. 14, pp. 1777–1782, 2002.
K. Klausen, K. Borch-Johnsen, B. Feldt-Rasmussen et al., “Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes,” Circulation, vol. 110, no. 1, pp. 32–35, 2004.
J. F. E. Mann, H. C. Gerstein, J. Poque, J. Bosch, and S. Yusuf, “Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial,” Annals of Internal Medicine, vol. 134, no. 8, pp. 629–636, 2001.
M. Jeansson, K. Bjorck, O. Tenstad, and B. Haraldsson, “Adriamycin alters glomerular endothelium to induce proteinuria,” Journal of the American Society of Nephrology, vol. 20, no. 1, pp. 114–122, 2009.
M. Jeansson and B. Haraldsson, “Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier,” American Journal of Physiology, vol. 290, no. 1, pp. F111–F116, 2006.
V. Eremina, H. J. Baelde, and S. E. Quaggin, “Role of the VEGF-A signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier,” Nephron—Physiology, vol. 106, no. 2, pp. p32–p37, 2007.
S. C. Satchell and F. Braet, “Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier,” American Journal of Physiology, vol. 296, no. 5, pp. F947–F956, 2009.
Q. Fan, Y. Xing, J. Ding, and N. Guan, “Reduction in VEGF protein and phosphorylated nephrin associated with proteinuria in adriamycin nephropathy rats,” Nephron—Experimental Nephrology, vol. 111, no. 4, pp. e92–e102, 2009.
L. Fan, T. Wakayama, S. Yokoyama, O. Amano, and S. Iseki, “Downregulation of vascular endothelial growth factor and its receptors in the kidney in rats with puromycin aminonucleoside nephrosis,” Nephron, vol. 90, no. 1, pp. 95–102, 2002.
Y. Horita, M. Miyazaki, T. Koji et al., “Expression of vascular endothelial growth factor and its receptors in rats with protein-overload nephrosis,” Nephrology Dialysis Transplantation, vol. 13, no. 10, pp. 2519–2528, 1998.
E. Bailey, M. J. Bottomley, S. Westwell et al., “Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation,” Journal of Clinical Pathology, vol. 52, no. 10, pp. 735–738, 1999.
K. Matsumoto and K. Kanmatsuse, “Elevated vascular endothelial growth factor levels in the urine of patients with minimal-change nephrotic syndrome,” Clinical Nephrology, vol. 55, no. 4, pp. 269–274, 2001.
B. G. Hudson, K. Tryggvason, M. Sundaramoorthy, and E. G. Neilson, “Alport's syndrome, Goodpasture's syndrome, and type IV collagen,” The New England Journal of Medicine, vol. 348, no. 25, pp. 2543–2556, 2003.
M. J. van den Hoven, T. J. Wijnhoven, J. P. Li et al., “Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria,” Kidney International, vol. 73, no. 3, pp. 278–287, 2008.
M. Zenker, M. Pierson, P. Jonveaux, and A. Reis, “Demonstration of two novel LAMB2 mutations in the original Pierson syndrome family reported 42 years ago,” American Journal of Medical Genetics Part A, vol. 138, no. 1, pp. 73–74, 2005.
C. Dai, D. B. Stolz, S. I. Bastacky et al., “Essential role of integrin-linked kinase in podocyte biology: bridging the integrin and slit diaphragm signaling,” Journal of the American Society of Nephrology, vol. 17, no. 8, pp. 2164–2175, 2006.
C. El-Aouni, N. Herbach, S. M. Blattner et al., “Podocyte-specific deletion of integrin-linked kinase results in severe glomerular basement membrane alterations and progressive glomerulosclerosis,” Journal of the American Society of Nephrology, vol. 17, no. 5, pp. 1334–1344, 2006.
Y. S. Kang, Y. Li, C. Dai, L. P. Kiss, C. Wu, and Y. Liu, “Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria,” Kidney International, vol. 78, no. 4, pp. 363–373, 2010.
H. Kurihara, J. M. Anderson, D. Kerjaschki, and M. G. Farquhar, “The altered glomerular filtration slits seen in puromycin aminonucleoside nephrosis and protamine sulfate-treated rats contain the tight junction protein ZO-1,” American Journal of Pathology, vol. 141, no. 4, pp. 805–816, 1992.
E. Torres-Rasgado, G. Fouret, M. A. Carbonneau, and C. L. Leger, “Peroxynitrite mild nitration of albumin and LDL-albumin complex naturally present in plasma and tyrosine nitration rate-albumin impairs LDL nitration,” Free Radical Research, vol. 41, no. 3, pp. 367–375, 2007.
H. Putaala, R. Soininen, P. Kilpelainen, J. Wartiovaara, and K. Tryggvason, “The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death,” Human Molecular Genetics, vol. 10, no. 1, pp. 1–8, 2001.
M. Orikasa, K. Matsui, T. Oite, and F. Shimizu, “Massive proteinuria induced in rats by a single intravenous injection of a monoclonal antibody,” Journal of Immunology, vol. 141, no. 3, pp. 807–814, 1988.
G. M. Barletta, I. A. Kovari, R. K. Verma, D. Kerjaschki, and L. B. Holzman, “Nephrin and Neph1 co-localize at the podocyte foot process intercellular junction and form cis hetero-oligomers,” The Journal of Biological Chemistry, vol. 278, no. 21, pp. 19266–19271, 2003.
J. Wartiovaara, L. G. Ofverstedt, J. Khoshnoodi et al., “Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography,” Journal of Clinical Investigation, vol. 114, pp. 1475–1483, 2004.
S. Sours, J. Du, S. Chu, M. Ding, X. J. Zhou, and R. Ma, “Expression of canonical transient receptor potential (TRPC) proteins in human glomerular mesangial cells,” American Journal of Physiology, vol. 290, no. 6, pp. F1507–F1515, 2006.
S. Graham, M. Ding, S. Sours-Brothers, T. Yorio, J. X. Ma, and R. Ma, “Downregulation of TRPC6 protein expression by high glucose, a possible mechanism for the impaired Ca2+ signaling in glomerular mesangial cells in diabetes,” American Journal of Physiology, vol. 293, no. 4, pp. F1381–F1390, 2007.
C. C. Moller, C. Wei, M. M. Altintas et al., “Induction of TRPC6 channel in acquired forms of proteinuric kidney disease,” Journal of the American Society of Nephrology, vol. 18, no. 1, pp. 29–36, 2007.
T. Nijenhuis, A. J. Sloan, J. G. J. Hoenderop et al., “Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway,” American Journal of Pathology, vol. 179, no. 4, pp. 1719–1732, 2011.
G. S. Hill, K. E. Karoui, A. Karras et al., “Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. I. Immunohistochemical studies,” Kidney International, vol. 79, no. 6, pp. 635–642, 2011.
S. Zhao, X. Gu, L. J. Groome, and Y. Wang, “Decreased nephrin and GLEPP-1, but increased VEGF, Flt-1, and nitrotyrosine, expressions in kidney tissue sections from women with preeclampsia,” Reproductive Sciences, vol. 16, no. 10, pp. 970–979, 2009.
S. Breiteneder-Geleff, K. Matsui, A. Soleiman et al., “Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis,” American Journal of Pathology, vol. 151, no. 4, pp. 1141–1152, 1997.
K. Koop, M. Eikmans, M. Wehland et al., “Selective loss of podoplanin protein expression accompanies proteinuria and precedes alterations in podocyte morphology in a spontaneous proteinuric rat model,” American Journal of Pathology, vol. 173, no. 2, pp. 315–326, 2008.
R. Loewith, E. Jacinto, S. Wullschleger et al., “Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control,” Molecular Cell, vol. 10, no. 3, pp. 457–468, 2002.
N. Ito, Y. Nishibori, Y. Ito et al., “MTORC1 activation triggers the unfolded protein response in podocytes and leads to nephrotic syndrome,” Laboratory Investigation, vol. 91, no. 11, pp. 1584–1595, 2011.
G. K. Rangan and J. D. Coombes, “Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis,” Nephrology Dialysis Transplantation, vol. 22, no. 8, pp. 2175–2182, 2007.
R. G. B. Bonegio, R. Fuhro, Z. Wang et al., “Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy,” Journal of the American Society of Nephrology, vol. 16, no. 7, pp. 2063–2072, 2005.
R. Kurayama, N. Ito, Y. Nishibori et al., “Role of amino acid transporter LAT2 in the activation of mTORC1 pathway and the pathogenesis of crescentic glomerulonephritis,” Laboratory Investigation, vol. 91, no. 7, pp. 992–1006, 2011.
J. Torras, I. Herrero-Fresneda, O. Gulias et al., “Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage,” Nephrology Dialysis Transplantation, vol. 24, no. 12, pp. 3632–3640, 2009.
B. Hartleben, M. G？del, C. Meyer-Schwesinger et al., “Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice,” Journal of Clinical Investigation, vol. 120, no. 4, pp. 1084–1096, 2010.
G. Genovese, S. J. Tonna, A. U. Knob et al., “A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9,” Kidney International, vol. 78, no. 7, pp. 698–704, 2010.
S. Tzur, S. Rosset, R. Shemer et al., “Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene,” Human Genetics, vol. 128, no. 3, pp. 345–350, 2010.
S. M. Madhavan, J. F. O'Toole, M. Konieczkowski, S. Ganesan, L. A. Bruggeman, and J. R. Sedor, “APOL1 localization in normal kidney and nondiabetic kidney disease,” Journal of the American Society of Nephrology, vol. 22, no. 11, pp. 2119–2128, 2011.
B. Lewko, M. Go？os, E. Latawiec, S. Angielski, and J. Stepinski, “Regulation of cGMP synthesis in cultured podocytes by vasoactive hormones,” Journal of Physiology and Pharmacology, vol. 57, no. 4, pp. 599–610, 2006.
A. Patzak, E. Lai, P. B. Persson, and A. E. G. Persson, “Angiotensin II-nitric oxide interaction in glomerular arterioles,” Clinical and Experimental Pharmacology and Physiology, vol. 32, no. 5-6, pp. 410–414, 2005.
G. Gauquelin, E. L. Schiffrin, and R. Garcia, “Downregulation of glomerular and vascular atrial natriuretic factor receptor subtypes by angiotensin II,” Journal of Hypertension, vol. 9, no. 12, pp. 1151–1160, 1991.
I. Nakayama, Y. Kawahara, T. Tsuda, M. Okuda, and M. Yokoyama, “Angiotensin II inhibits cytokine-stimulated inducible nitric oxide synthase expression in vascular smooth muscle cells,” The Journal of Biological Chemistry, vol. 269, no. 15, pp. 11628–11633, 1994.
D. Kim, T. Aizawa, H. Wei et al., “Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling,” Journal of Molecular and Cellular Cardiology, vol. 38, no. 1, pp. 175–184, 2005.
M. Golos, B. Lewko, E. Bryl et al., “Effect of angiotensin II on ANP-dependent guanylyl cyclase activity in cultured mouse and rat podocytes,” Kidney and Blood Pressure Research, vol. 25, no. 5, pp. 296–302, 2002.
L. M. Russo, R. M. Sandoval, M. McKee et al., “The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states,” Kidney International, vol. 71, no. 6, pp. 504–513, 2007.
F. Theilig, W. Kriz, T. Jerichow et al., “Abrogation of protein uptake through megalin-deficient proximal tubules does not safeguard against tubulointerstitial injury,” Journal of the American Society of Nephrology, vol. 18, no. 6, pp. 1824–1834, 2007.
J. A. Joles, U. Kunter, U. Janssen et al., “Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats,” Journal of the American Society of Nephrology, vol. 11, no. 4, pp. 669–683, 2000.
H. S. Lee, “Mechanisms and consequences of hypertriglyceridemia and cellular lipid accumulation in chronic kidney disease and metabolic syndrome,” Histology and Histopathology, vol. 26, no. 12, pp. 1599–1610, 2011.
P. Ruggenenti, A. Perna, G. Gherardi et al., “Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria,” The Lancet, vol. 354, no. 9176, pp. 359–364, 1999.
E. J. Lewis, L. G. Hunsicker, W. R. Clarke et al., “Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes,” The New England Journal of Medicine, vol. 345, no. 12, pp. 851–860, 2001.
B. M. Brenner, M. E. Cooper, D. de Zeeuw et al., “Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy,” The New England Journal of Medicine, vol. 345, no. 12, pp. 861–869, 2001.
G. Maschio, D. Alberti, G. Janin et al., “Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency,” The New England Journal of Medicine, vol. 334, no. 15, pp. 939–945, 1996.
J. E. Toblli, G. DeRosa, G. Cao, P. Piorno, and P. Pagano, “ACE inhibitor and angiotensin type I receptor antagonist in combination reduce renal damage in obese Zucker rats,” Kidney International, vol. 65, no. 6, pp. 2343–2359, 2004.
H. H. Parving, F. Persson, J. B. Lewis, E. J. Lewis, and N. K. Hollenberg, “Aliskiren combined with losartan in type 2 diabetes and nephropathy,” The New England Journal of Medicine, vol. 358, no. 23, pp. 2433–2446, 2008.
U. F. Mehdi, B. Adams-Huet, P. Raskin, G. L. Vega, and R. D. Toto, “Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 20, no. 12, pp. 2641–2650, 2009.
M. Epstein, G. H. Williams, M. Weinberger et al., “Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes,” Clinical Journal of the American Society of Nephrology, vol. 1, no. 5, pp. 940–951, 2006.
A. S. de Vriese, R. G. Tilton, M. Elger, C. C. Stephan, W. Kriz, and N. H. Lameire, “Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes,” Journal of the American Society of Nephrology, vol. 12, no. 5, pp. 993–1000, 2001.
K. Ichinose, Y. Maeshima, Y. Yamamoto et al., “2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice,” Diabetes, vol. 55, no. 5, pp. 1232–1242, 2006.
S. H. Sung, F. N. Ziyadeh, A. Wang, P. E. Pyagay, Y. S. Kanwar, and S. Chen, “Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice,” Journal of the American Society of Nephrology, vol. 17, no. 11, pp. 3093–3104, 2006.
Y. Masuda, A. Shimizu, M. Kataoka et al., “Inhibition of capillary repair in proliferative glomerulonephritis results in persistent glomerular inflammation with glomerular sclerosis,” Laboratory Investigation, vol. 90, no. 10, pp. 1468–1481, 2010.